David Bottomley

7.8k citations

58 papers · 2.4k indexed · 3 hit papers · h-index 21

Radiation top 0.5%
- Advanced Radiotherapy Techniques 15
Pulmonary and Respiratory Medicine top 1%
- Prostate Cancer Treatment and Research 40
- Prostate Cancer Diagnosis and Treatment 31
Radiology, Nuclear Medicine and Imaging top 2%
- Radiopharmaceutical Chemistry and Applications 16
- Boron Compounds in Chemistry 4
Urology top 5%
Oncology top 10%
- Cancer Treatment and Pharmacology 4
Surgery
- Bladder and Urothelial Cancer Treatments 7
Biomedical Engineering
- Advanced X-ray and CT Imaging 4

Co-authors: Bashar Al‐Qaisieh Brendan Carey D. Ash Matthew R. Sydes Isabel Syndikus David P. Dearnaley Mahesh Parmar Robert Huddart
Cited by: Radiation Pulmonary and Respiratory Medicine Radiology, Nuclear Medicine and Imaging
Journals: Journal of Clinical Oncology (8 papers)Radiotherapy and Oncology (7 papers)International Journal of Radiation Oncology*Biology*Physics (5 papers)
Partner nations: United Kingdom United States Sweden

In The Last Decade

David Bottomley

57 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by David Bottomley

Since Specialization

Citations

This map shows the geographic impact of David Bottomley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Bottomley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Bottomley more than expected).

Fields of papers citing papers by David Bottomley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Bottomley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Bottomley. The network helps show where David Bottomley may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Bottomley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Bottomley Line = papers co-authored together David Bottomley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·Heather Payne,Jamshed Bomanji,David Bottomley,Andrew Scarsbrook,Eugene Teoh,(unknown)	2022	2
2	Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer Journal of Contemporary Brachytherapy ·Finbar Slevin,Արման Սարգսյան,Bashar Al‐Qaisieh,Peter Bownes,Erin Brooker Lozott,Jonathan Smith,David Bottomley,Ann Henry	2020	8
3	Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer Clinical and Translational Radiation Oncology ·Finbar Slevin,Samantha Hodgson,S. Rodda,Peter Bownes,David Bottomley,호민 임,Bashar Al‐Qaisieh,Hemanth Kavti,徹楡木,Erin Brooker Lozott,Jonathan Smith,Ann Henry	2020	21
4	A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy Clinical and Translational Radiation Oncology ·Finbar Slevin,S. Rodda,Peter Bownes,Louise Murray,David Bottomley,Clare Wilkinson,호민 임,Bashar Al‐Qaisieh,Hemanth Kavti,徹楡木,Erin Brooker Lozott,Jonathan Smith,Ann Henry	2019	15
5	Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer Clinical Oncology ·Sameer A. Parikh,Louise Murray,OnnenGrauhan,David Bottomley,Omar Din,Sanjay Dixit,Catherine Ferguson,Catherine Handforth,Lisa Joseph,実吉健策,F Papino,Graham A. Wright,Ann Henry	2018	39
6	Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial European Urology ·Christopher Parker,Steven E. Finkelstein,Jeff M. Michalski,Joe M. O’Sullivan,Øyvind S. Bruland,Nicholas J. Vogelzang,Robert E. Coleman,Sten Nilsson,Oliver Sartor,Rui Li,Monica Seger,David Bottomley	2016	51
7	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trialbreakdown → The Lancet Oncology ·Peter Hoskin,Oliver Sartor,Joe M. O’Sullivan,Dag Clement Johannessen,Svein Inge Helle,John Logue,David Bottomley,Sten Nilsson,Nicholas J. Vogelzang,Fang Fang,Mona Wahba,Anne-Kirsti Aksnes,Christopher Parker	2014	290
8	Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trialbreakdown → The Lancet Oncology ·David P. Dearnaley,Gordana Jovic,Isabel Syndikus,Vincent Khoo,Richard Cowan,John D. Graham,Edwin Aird,David Bottomley,Robert Huddart,Chakiath Jose,J. H. Matthews,Jeremy Millar,Claire Murphy,John M. Russell,Christopher Scrase,Mahesh Parmar,Matthew R. Sydes	2014	344
9	Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases European Journal of Cancer ·Chris Parker,Daniel Heinrich,David Bottomley,Peter Hoskin,Lars Franzén,A. Solberg,P. C Wilken,Jonathan Reuning‐Scherer,C. Gillies O'Bryan-Tear,Sten Nilsson	2013	2
10	Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy Radiotherapy and Oncology ·Anna Tran,علی صیرفیان,R. Swindell,Peter Hoskin,David Bottomley,John Logue,James Wylie	2013	13
11	Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). Journal of Clinical Oncology ·Oliver Sartor,Daniel Heinrich,Joe M. O’Sullivan,Sophie D. Fosså,Aleš Chodacki,Paweł Wiechno,John Logue,美智雄増田,Anders Widmark,Dag Clement Johannessen,Sten Nilsson,Peter Hoskin,David Bottomley,Robert E. Coleman,Nicholas J. Vogelzang,C. Gillies O'Bryan-Tear,J. Garcia‐Vargas,Minghua Shan,Chris Parker	2012	12
12	Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10years Radiotherapy and Oncology ·Nicholas P. Munro,Bashar Al‐Qaisieh,Peter Bownes,Jonathan Smith,Brendan Carey,David Bottomley,D. Ash,Ann Henry	2010	27
13	Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trialbreakdown → The Lancet Oncology ·David P. Dearnaley,Matthew R. Sydes,John D. Graham,Edwin Aird,David Bottomley,Richard Cowan,Robert Huddart,Chakiath Jose,J. H. Matthews,Jeremy Millar,Andrea Moore,Rachel C. Morgan,John M. Russell,Christopher Scrase,Richard Stephens,Isabel Syndikus,Mahesh Parmar	2007	686
14	Recto‐urethral fistula following brachytherapy for localized prostate cancer Colorectal Disease ·David Shakespeare,D. Mitchell,B. Carey,P J Finan,Ann Henry,D. Ash,David Bottomley,Bashar Al‐Qaisieh	2006	32
15	Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds Radiotherapy and Oncology ·David Bottomley,D. Ash,Bashar Al‐Qaisieh,Brendan Carey,Joji Joseph,Devin Farris,Magnusson Håkan	2006	48
16	The use of CT-MR image registration to define target volumes in pelvic radiotherapy in the presence of bilateral hip replacements British Journal of Radiology ·Natalie Charnley,Ashley M. Morgan,Evan Thomas,Stuart D. Wilson,Dr.Abusabah Elfatieh Elemam Elnor,Don Wilson,David Bottomley	2005	17
17	Prostate‐specific antigen relapse‐free survival in patients with localized prostate cancer treated by brachytherapy British Journal of Urology ·Joji Joseph,Bashar Al‐Qaisieh,Daniel Ash,David Bottomley,Brendan Carey	2004	32
18	Impact of prostate volume evaluation by different observers on CT-based post-implant dosimetry Radiotherapy and Oncology ·Bashar Al‐Qaisieh,D. Ash,David Bottomley,Brendan Carey	2002	64
19	Iodine Systematics in the Ground Water of a Natural Setting AGUFM ·Xiao Li-min,Ian Clark,T. Kotzer,David Bottomley	2001	1
20	Short‐term morbidity and acceptability of ¹²⁵ iodine implantation for localized carcinoma of the prostate British Journal of Urology ·Hoda Al‐Booz,D. Ash,David Bottomley,B. Carey	1999	13

About David Bottomley

David Bottomley is a scholar working on Radiation, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 58 papers that have together received 2.4k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (40 papers), Prostate Cancer Diagnosis and Treatment (31 papers), Radiopharmaceutical Chemistry and Applications (16 papers), Advanced Radiotherapy Techniques (15 papers), Bladder and Urothelial Cancer Treatments (7 papers), Boron Compounds in Chemistry (4 papers), Cancer Treatment and Pharmacology (4 papers) and Advanced X-ray and CT Imaging (4 papers). The work is most often cited by research in Radiation (1.1k citations), Pulmonary and Respiratory Medicine (2.1k citations) and Radiology, Nuclear Medicine and Imaging (669 citations). David Bottomley has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Bashar Al‐Qaisieh, Brendan Carey, D. Ash, Matthew R. Sydes, Isabel Syndikus, David P. Dearnaley, Mahesh Parmar, Robert Huddart, John D. Graham and John M. Russell. Their work appears in journals such as Journal of Clinical Oncology, Radiotherapy and Oncology, International Journal of Radiation Oncology*Biology*Physics, Clinical Oncology and British Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact